
News|Articles|October 1, 2004
High-dose simvastatin fails to achieve primary end point in trial of ACS
Initiating high-dose simvastatin (Zocor, Merck) early after an acute coronary syndrome (ACS) event does not result in significantly superior clinical outcomes compared to delayed initiation of low-dose simvastatin.This major finding of phase Z of the A to Z Trial is in contrast to the results of 2 previous clinical trials in which aggressive therapy with atorvastatin (Lipitor, Pfizer) was found to be superior to less aggressive statin therapy in reducing the risk of adverse clinical events in ACS patients.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
3
Cancer survival fell and deaths rose during first two years of COVID-19
4
TrumpRx launches; some experts question its long-term value
5























